Aurinia Pharmaceuticals
AUPH
189 hedge funds and large institutions have $421M invested in Aurinia Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 57 increasing their positions, 54 reducing their positions, and 31 closing their positions.
87% more call options, than puts
Call options by funds: $23.8M | Put options by funds: $12.7M
3.61% more ownership
Funds ownership: 35.8% → 39.41% (+3.6%)
6% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 54
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less funds holding
Funds holding: 199 → 189 (-10)
18% less capital invested
Capital invested by funds: $510M → $421M (-$89.8M)
26% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 31
Top Buyers
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$49.1M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$16.3M |
| 3 |
AC
Armistice Capital
New York
|
+$6.27M |
| 4 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
+$4.91M |
| 5 |
Two Sigma Investments
New York
|
+$4.54M |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$12.3M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$8.14M |
| 3 |
N
Natixis
Paris,
France
|
-$7.55M |
| 4 |
KAS
Kestra Advisory Services
Austin,
Texas
|
-$5.87M |
| 5 |
Barclays
London,
United Kingdom
|
-$3.33M |
AUPH Hedge Fund Activity: Q3 2022 in Review
189 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q3 2022, worth a combined $421M — down 18% from $510M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of AUPH and 23 opened new positions — a net loss of 8 holders — while 54 trimmed existing stakes and 57 added.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $49.1M. The largest seller was Morgan Stanley, cutting an estimated $12.3M.
- 189 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q3 2022, down from 199 in Q2 2022.
- Funds reported $421M of Aurinia Pharmaceuticals stock for Q3 2022, down 18% quarter-over-quarter.
- 23 funds opened new Aurinia Pharmaceuticals positions in Q3 2022 and 31 closed out, a net change of -8 holders.
- The largest Aurinia Pharmaceuticals buyer in Q3 2022 was Deep Track Capital, an estimated $49.1M added.
- The largest Aurinia Pharmaceuticals seller in Q3 2022 was Morgan Stanley, an estimated $12.3M sold.
Based on aggregated 13F filings for Q3 2022.